OKYO Pharma, of London, announced Dec. 13 that its first drug candidate, OK-101, developed to treat dry eye disease as an anti-inflammatory, also showed potent ocular pain reducing properties in a mouse model. OK-101 is a novel, long-acting G protein-coupled receptor-based lipidated chemerin peptide developed to bind to ChemR23 receptors in the eye and interrupt the inflammatory response.
Kiora Reports KIO-101 is Safe and Tolerable for Dry Eye Disease
Kiora Pharmaceuticals announced topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops. The study evaluated 24 healthy subjects and 21 patients diagnosed with ocular surface inflammation, a driver of dry eye disease. The results demonstrated favorable safety and tolerability of KIO-101 as well as statistically significant improvements in conjunctival hyperemia, a key inclusion criterion for the 21 patients …
Stuart Therapeutics Completes Enrollment in Phase II Trial for Dry Eye Candidate
Stuart Therapeutics, of Stuart, Florida, announced Sept. 8 that it had completed enrollment of 150 patients in a Phase II clinical trial of its eye drop candidate ST-100 in dry eye disease. The multi-center, randomized, double-masked study will evaluate two different dose levels vs. placebo. The company, founded in 2017, has exclusively licensed the worldwide rights to a family of …
Low-Level Light Therapy
This procedure is a simple and effective option for treating meibomian gland dysfunction. Many options are available for the treatment of meibomian gland dysfunction (MGD), but most insurance plans cover only pharmaceuticals. Low-level light therapy (LLLT) is a low-cost entry point to MGD management. It is effective both as a standalone procedure with the Equinox (Espansione Group) and in combination …
Dry eye disease cream demonstrates improvement, rapid onset of action in phase 2 trial
AXR-270 demonstrated ‘statically and clinically meaningful improvement’ in patients with dry eye disease associated with meibomian gland dysfunction, according to a press release from AxeroVision.
Complexity Gaming Kicks Off Year-Long Partnership With Alcon
Esports company Complexity Gaming announced a partnership with Alcon. The partnership will designate Alcon’s signature brand of lubricant eye drops, Systane, as the first official eye care partner of Complexity Gaming.
